Werewolf Therapeutics, Inc.
HOWL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -90.5% | 21.6% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 3.8% | 91.2% | 84.7% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,397.6% | -162.8% | -312.8% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,740.8% | -187.4% | -328.1% | – |
| EPS Diluted | -1.63 | -1.05 | -1.86 | -10.94 |
| % Growth | -55.2% | 43.5% | 83% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |